Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2022) Felipe Batalini et al.   CLINICAL CANCER RESEARCH

175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

(2022) F. Cardoso et al.   ANNALS OF ONCOLOGY

Abstract GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST

(2022) Fabrice André et al.   CANCER RESEARCH

Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

(2022) Stephen Chia et al.   CANCER RESEARCH

Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study

(2022) Dejan Juric et al.   CANCER RESEARCH

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα

(2022) Emily J. Hanan et al.   Journal of Medicinal Chemistry

Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines

(2022) Maria Rosaria Ambrosio et al.   Cancers

Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors

(2021) Yanyan Cai et al.   CANCER RESEARCH

Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer

(2021) Priyanka Sharma et al.   CLINICAL CANCER RESEARCH

CDK 4/6 and PI3K inhibitors: a new promise for patients with HER2‐positive breast cancer

(2021) Elisa Agostinetto et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer

(2021) Komal Jhaveri et al.   CLINICAL CANCER RESEARCH

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

(2021) Eva Maria Ciruelos et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

(2021) Hope S Rugo et al.   LANCET ONCOLOGY

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity

(2021) Sarah Christine Elisabeth Wright et al.   Cancers

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway

(2021) Huayu Hu et al.   Annals of Translational Medicine

LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

(2021) M. Oliveira et al.   ANNALS OF ONCOLOGY

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

(2021) Jorge Gómez Tejeda Zañudo et al.   CANCER RESEARCH

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

(2021) Komal Jhaveri et al.   CLINICAL CANCER RESEARCH

Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study

(2021) Giuseppe Curigliano et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis

(2021) John Hang Leung et al.   Expert Opinion On Drug Safety

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

(2021) David Starks et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.

(2021) Diana Bello et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K inhibitors are finally coming of age

(2021) Bart Vanhaesebroeck et al.   NATURE REVIEWS DRUG DISCOVERY

RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy

(2021) Kyung W Song et al.   Cancer Discovery

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

(2020) F. Mosele et al.   ANNALS OF ONCOLOGY

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer

(2020) Sean P. Kennedy et al.   ONCOGENE

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

(2020) Sanxing Guo et al.   Cancer Research and Treatment

Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer

(2020) H.S. Rugo et al.   ANNALS OF ONCOLOGY

Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis

(2020) Yiqun Han et al.   CURRENT PROBLEMS IN CANCER

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

(2020) Ramesh K. Ramanathan et al.   Targeted Oncology

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

(2020) Lacey M. Litchfield et al.   Oncotarget

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

(2020) Anja Welt et al.   Cancer Medicine

A Phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer

(2020) Yen-Shen Lu et al.   CLINICAL CANCER RESEARCH

352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)

(2020) S.A. Hurvitz et al.   ANNALS OF ONCOLOGY

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer

(2020) Sara M. Tolaney et al.   CLINICAL CANCER RESEARCH

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

(2020) Javier Pascual et al.   Cancer Discovery

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis

(2020) Shu Wang et al.   Biomed Research International

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

(2020) H.P. Eikesdal et al.   ANNALS OF ONCOLOGY

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

(2020) S. Dent et al.   ANNALS OF ONCOLOGY

Mechanisms of PTEN loss in cancer: It’s all about diversity

(2019) Virginia Álvarez-Garcia et al.   SEMINARS IN CANCER BIOLOGY

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

(2019) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).

(2019) Sarah Sammons et al.   JOURNAL OF CLINICAL ONCOLOGY

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

(2019) Vandana G. Abramson et al.   BREAST CANCER RESEARCH AND TREATMENT

A Systematic Literature Review Of The Prognostic And Predictive Value Of Pik3ca Mutations In Hr+/Her2–Metastatic Breast Cancer

(2019) Lea E. Mollon et al.   Clinical Breast Cancer

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

(2019) Richard D. Baird et al.   CLINICAL CANCER RESEARCH

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2019) Cristina Saura et al.   LANCET ONCOLOGY

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

(2019) Neil Vasan et al.   SCIENCE

TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer

(2019) Brian D. Lehmann et al.   CLINICAL CANCER RESEARCH

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

(2018) Sarika Jain et al.   BREAST CANCER RESEARCH AND TREATMENT

HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3

(2018) Ana Ruiz-Saenz et al.   CANCER RESEARCH

A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer

(2018) Autumn J. McRee et al.   Clinical Breast Cancer

Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer

(2018) Maura N. Dickler et al.   CLINICAL CANCER RESEARCH

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

(2018) Navid Sobhani et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

(2018) Angelo Di Leo et al.   LANCET ONCOLOGY

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

(2018) Mario Campone et al.   EUROPEAN JOURNAL OF CANCER

Mechanisms behind resistance to PI3K Inhibitor treatment induced by the PIM kinase

(2018) Jin H. Song et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

(2018) Benjamin D. Hopkins et al.   NATURE

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

(2018) Nicholas C. Turner et al.   CLINICAL CANCER RESEARCH

Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer

(2018) Marcus D. Goncalves et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

(2018) Dejan Juric et al.   JAMA Oncology

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)

(2017) Sibylle Loibl et al.   EUROPEAN JOURNAL OF CANCER

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

(2017) Mathilde Guerin et al.   EUROPEAN JOURNAL OF CANCER

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

(2017) Dejan Juric et al.   Cancer Discovery

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

(2016) A. Patnaik et al.   ANNALS OF ONCOLOGY

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)

(2016) M. Martín et al.   ANNALS OF ONCOLOGY

PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

(2016) S. Loibl et al.   ANNALS OF ONCOLOGY

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

(2016) P. Vuylsteke et al.   ANNALS OF ONCOLOGY

Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer

(2016) Jose Baselga et al.   CANCER RESEARCH

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER + Breast Cancer

(2016) Sarah R. Hosford et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer

(2016) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Ian E Krop et al.   LANCET ONCOLOGY

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

(2016) X. Le et al.   Cancer Discovery

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer

(2015) Cristina Saura et al.   CANCER RESEARCH

Metabolic Reprogramming of Immune Cells in Cancer Progression

(2015) Subhra K. Biswas   IMMUNITY

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations

(2015) M. A. Bonelli et al.   MOLECULAR CANCER THERAPEUTICS

Synergy in activating class I PI3Ks

(2015) John E. Burke et al.   TRENDS IN BIOCHEMICAL SCIENCES

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

(2014) C. Saura et al.   CLINICAL CANCER RESEARCH

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

(2014) N. A. O'Brien et al.   CLINICAL CANCER RESEARCH

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

(2014) Jordi Rodon et al.   INVESTIGATIONAL NEW DRUGS

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

(2014) Ingrid A. Mayer et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

(2014) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis

(2014) Bo Pang et al.   Scientific Reports

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

(2013) Violeta Serra et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

(2013) Chudi O. Ndubaku et al.   JOURNAL OF MEDICINAL CHEMISTRY

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

(2013) H. Ebi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients

(2012) FR Mangone et al.   Clinics

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

(2011) Yuting Ma et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform

(2011) Timothy P. Heffron et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer

(2010) Todd W. Miller et al.   JOURNAL OF CLINICAL INVESTIGATION

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3

(2010) A Chakrabarty et al.   ONCOGENE

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE

Helical domain and kinase domain mutations in p110  of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

(2008) L. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA